Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CK-3773274 (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor. It is under phase 3 clinical development fot the treatment of obstructive hypertrophic cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-3773274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2023
Details:
CK-274 (aficamten), is small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program, which is investigated for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
CK-274 (aficamten), is small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program, which is investigated for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-3773274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
CK-4021586 (CK-586) is a novel, selective, oral, small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction (HFpEF).
Lead Product(s): CK-586
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-4021586
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
AMG 423 (omecamtiv mecarbil) is a selective, small molecule cardiac myosin activator, designed to directly target the contractile mechanisms of the heart, binding to and recruiting more cardiac myosin heads to interact with actin during systole for the treatment of HFrEF.
Lead Product(s): Omecamtiv Mecarbil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AMG 423
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
Omecamtiv mecarbil (AMG 423), is an investigational, selective, small molecule cardiac myosin activator, the first of a novel class of myotropes designed to directly target the contractile mechanisms of the heart, binding to and recruiting more cardiac myosin.
Lead Product(s): Omecamtiv Mecarbil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AMG 423
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Preclinical research has shown that AMG 423 (omecamtiv mecarbil) increases cardiac contractility without increasing intracellular myocyte calcium concentrations or myocardial oxygen consumption.
Lead Product(s): Omecamtiv Mecarbil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AMG 423
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2022
Details:
Reldesemtiv (CK-2127107), is an investigational, selective, small molecule fast skeletal muscle troponin activator (FSTA) arising from Cytokinetics’ skeletal muscle contractility program.
Lead Product(s): Reldesemtiv
Therapeutic Area: Neurology Product Name: CK-2127107
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
CK-3828136 (CK-136) is a novel, selective, oral, small molecule cardiac troponin activator. In preclinical models, CK-136 increased myocardial contractility by binding to cardiac troponin through an allosteric mechanism.
Lead Product(s): CK-136
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-3828136
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
Cytokinetics is developing AMG 423 (omecamtiv mecarbil), a novel, selective cardiac myosin activator for the potential treatment for heart failure with reduced ejection fraction (HFrEF).
Lead Product(s): Omecamtiv Mecarbil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AMG 423
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022